United Health Group, the largest U.S. health insurer by enrollees, was under pressure after Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, sent the conglomerate's chief executive, ...
Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...
Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...
It’s time to treat obesity as a chronic disease and have Medicare cover these life-changing AOMs. By taking action now, we ...
Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...
Opinion: It’s time we prioritize innovation and invest in solutions that truly address the root cause of this chronic and ...
1d
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...
Hosted on MSN1d
Medicare spending on diabetes drugs surged in 5 years: IGMedicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could ...
Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big ...
These findings support the claim that Medicare Advantage (MA) payments may be driven more by diagnosis and coding practices ...
Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...
Supplies of high-demand obesity drugs are improving – but they’re not easier to get - ‘There are a lot of people right now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback